IRLAB Therapeutics (Sweden) Today
| IRLAB-A Stock | SEK 14.75 0.20 1.34% |
Performance3 of 100
| Odds Of DistressLess than 23
|
IRLAB Therapeutics is trading at 14.75 as of the 31st of January 2025, a 1.34% down since the beginning of the trading day. The stock's open price was 14.95. IRLAB Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of February 2023 and ending today, the 31st of January 2025. Click here to learn more.
IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurological and neuropsychiatric disorders. Its pipeline candidates include IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinsons disease and Parkinson disease psychosis IRL752, a cortical enhancer for the treatment of Parkinson disease dementia and behavioral and psychological symptoms of dementia IRL626, a fast-off D2 antagonist for use in the treatment of schizophrenia P001, a cortical enhancer program for the treatment of attention disorders and IRL448IRL555, a followup Parkinsons disease program. The company has 51.79 M outstanding shares. More on IRLAB Therapeutics AB
Moving against IRLAB Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
IRLAB Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. IRLAB Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding IRLAB Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
IRLAB Therapeutics AB (IRLAB-A) is traded on Stockholm Exchange in Sweden and employs 31 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 525.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IRLAB Therapeutics's market, we take the total number of its shares issued and multiply it by IRLAB Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. IRLAB Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 51.79 M outstanding shares.
IRLAB Therapeutics AB has accumulated about 401.9 M in cash with 128.64 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.89.
Check IRLAB Therapeutics Probability Of Bankruptcy
Ownership AllocationIRLAB Therapeutics AB has a total of 51.79 Million outstanding shares. IRLAB Therapeutics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check IRLAB Ownership Details
IRLAB Therapeutics Risk Profiles
Although IRLAB Therapeutics' alpha and beta are two of the key measurements used to evaluate IRLAB Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.46 | |||
| Semi Deviation | 2.98 | |||
| Standard Deviation | 6.16 | |||
| Variance | 37.99 |
IRLAB Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in IRLAB Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
IRLAB Therapeutics Corporate Management
Elected by the shareholders, the IRLAB Therapeutics' board of directors comprises two types of representatives: IRLAB Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IRLAB. The board's role is to monitor IRLAB Therapeutics' management team and ensure that shareholders' interests are well served. IRLAB Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IRLAB Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Waters | Ex RD | Profile | |
| Maria Jalmelid | Chief Operations | Profile | |
| Joakim MD | Chief Officer | Profile | |
| Richard MBA | Chief Officer | Profile | |
| BSc BSc | Director HR | Profile | |
| Clas Sonesson | Chief Officer | Profile | |
| Viktor Siewertz | Chief Officer | Profile |
Other Information on Investing in IRLAB Stock
IRLAB Therapeutics financial ratios help investors to determine whether IRLAB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IRLAB with respect to the benefits of owning IRLAB Therapeutics security.